Compare BOX & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOX | ADMA |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.7B |
| IPO Year | 2015 | N/A |
| Metric | BOX | ADMA |
|---|---|---|
| Price | $30.60 | $19.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $38.67 | $28.50 |
| AVG Volume (30 Days) | 2.3M | ★ 2.3M |
| Earning Date | 12-02-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.13 | ★ 205.35 |
| EPS | ★ 1.24 | 0.86 |
| Revenue | ★ $1,150,898,000.00 | $488,559,000.00 |
| Revenue This Year | $9.07 | $22.19 |
| Revenue Next Year | $7.74 | $23.71 |
| P/E Ratio | $24.27 | ★ $22.52 |
| Revenue Growth | 7.21 | ★ 27.63 |
| 52 Week Low | $28.00 | $13.50 |
| 52 Week High | $38.80 | $25.67 |
| Indicator | BOX | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 53.64 |
| Support Level | $29.42 | $18.33 |
| Resistance Level | $30.69 | $19.94 |
| Average True Range (ATR) | 0.58 | 0.60 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 56.80 | 36.42 |
Box is a cloud-based content management platform that provides storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file, sync, and share provider. Over time, it built out and acquired workflow and security tools to evolve the pure-play FSS business into a content management business. Most recently, Box has been pursuing an AI-powered, intelligent content management strategy that can allow for metadata extraction and workflow automation.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.